miR-125a-5p could be considered a regulator of glycolipid metabolism in type 2 diabetes mellitus (T2DM), which can inhibit hepatic lipogenesis and gluconeogenesis and elevate glycogen synthesis by targeting STAT3 (15). The gene discussed is STAT3; the disease is type 2 diabetes mellitus.